Peptide Research Database
Access 7,487 peer-reviewed studies, clinical trials, and research papers on peptides. Filter by key research, study type, compound, and category. Direct links to full PubMed entries for comprehensive, evidence-based exploration.
From brittle ceramic to flexible shield: composition-tunable, lightweight gamma-ray shielding in lead-free MgFe2O4/HDPE nanocomposites.
This study found these findings establish computational composition-performance design maps, which require experimental validation, for lightweight, wearable and space-constrained radiation-protection applications.
Kane SN
Ionizing radiation shielding increasingly demands lightweight, non-toxic alternatives to conventional lead and concrete barriers. This work computationally assesses the gamma-ray attenuation, buildup and mechanical behavior of lead-free magnesium nanoferrite (MgFe2O4, MgF)/high-density polyethylene (HDPE) composites as a function of MgF loading. Five compositions (S1-S5), spanning 100-0 wt% MgF, were investigated. Mass and linear attenuation coefficients (MAC, LAC), half- and tenth-value layers, mean free path and buildup factors were computed over 0.015-15 MeV using Phy-X/PSD, and mechanical properties via the Voigt-Reuss-Hill approach with the rule of mixtures. All attenuation metrics varied monotonically with MgF content: pure MgF (S1) showed the highest LAC (0.3392 cm-1) and lowest half-value layer (2.04 cm) at 662 keV, although its MAC (0.0751 cm2/g) is lower than that of HDPE (0.0882 cm2/g) at this Compton-dominated energy, while HDPE-rich compositions retained mechanical flexibility, lower areal density, and superior fast-neutron moderation. Composite S2 (75MgF-25HDPE) emerged as the best practical compromise, combining strong attenuation with markedly lower brittleness than pure ceramic MgF. Benchmarked against lead, concrete and literature polymer systems, the present composites achieve a MAC within ∼11-24% of that of lead and above that of concrete at 662 keV, while being non-toxic and formable. MAC values from Phy-X/PSD, WinXCOM and EpiXS agree within RD ≤ 0.55% over 0.015-15 MeV, confirming inter-code consistency. These findings establish computational composition-performance design maps, which require experimental validation, for lightweight, wearable and space-constrained radiation-protection applications.
Kidney effects of tirzepatide across albuminuria, filtration markers, and clinical outcomes: a parent-trial-level systematic review and meta-analysis.
In a combined analysis of multiple studies, albuminuria lowering versus insulin was reproducible; hard-outcome benefit was population- and endpoint-dependent, and dedicated kidney-outcome trials remain needed.
Li S, Li S, Xu P, Jia J
Whether tirzepatide's kidney effects extend from albuminuria lowering to filtration preservation and clinical outcomes remains uncertain. We searched PubMed, Embase, and the Cochrane Library through August 2026 and mapped randomized reports to independent parent trials. Ten parent trials provided kidney data; eight informed each principal synthesis. Versus insulin, tirzepatide reduced urinary albumin-to-creatinine ratio by 27.0% (95% CI, 16.0%-36.6%; I2 = 37.8%; moderate certainty), whereas placebo-controlled evidence was uncertain (-18.1%; 95% CI, -43.2% to 18.3%; very low certainty). Fixed-time creatinine-based estimated glomerular filtration rate showed no clear benefit (0.36 mL/min/1.73 m2; 95% CI, -0.34 to 1.07; low certainty). In SURPASS-CVOT, approximate post hoc aggregate contrasts suggested larger high-risk effects for filtration and a hard-only composite, but were multiplicity-unadjusted and not formal individual-participant interaction tests. In that high-risk stratum, the hard-only hazard ratio versus dulaglutide was 0.70 (0.57-0.86), while end-stage kidney disease was not clearly reduced (1.04; 0.70-1.55). Albuminuria lowering versus insulin was reproducible; hard-outcome benefit was population- and endpoint-dependent, and dedicated kidney-outcome trials remain needed.
Weight loss at a cost: Semaglutide and PYY3-36 aggravate pre-existing metabolic osteoporosis in female Wistar rats.
In a rat study, collectively, these findings suggest that semaglutide modestly impairs bone health.
Kloock S, Zytner P, Geiger N, Sequeira V, Schmitt-Böhrer A, Felker J, Sarwar H, Weich A, Ignatius A, Fassnacht M, Haffner-Luntzer M, Dischinger U
Incretin mimetics like semaglutide and peptide YY3-36 (PYY3-36) reduce appetite and body weight, however their individual and combined effects on bone in the setting of metabolic disease and associated osteoporosis (MetOP) lack mechanistic insights. Here, female Wistar rats were randomized to: [1] Healthy control, [2] MetOP-Saline, [3] MetOP-Sema, [4] MetOP-PYY, [5] MetOP-Sema+PYY. Animals in group 2-5 received a "Western diet" in combination with nitric oxide synthase inhibitor L-NAME to induce MetOP as previously described. Randomization to treatments occurred in week 9. After 16 weeks, femora were collected for micro-computed-tomography, histological analysis, RNA-seq, and qPCR. Serum was analyzed for bone turnover markers and steroid profiles (LC-MS/MS). Semaglutide alone and in combination with PYY3-36 significantly reduced body weight. Semaglutide induced a modest reduction in trabecular bone volume fraction (BV/TV), whereas PYY3-36 alone and in combination with semaglutide caused more pronounced trabecular deterioration, with the combination group exhibiting increased trabecular separation. Cortical bone parameters were unaffected. Osteoclast numbers were increased in the semaglutide and PYY3-36 groups. Gene expression analysis demonstrated only mild changes in femora of semaglutide-treated rats, while PYY3-36 treatment significantly upregulated angiogenesis- and extracellular matrix-associated genes. Collectively, these findings suggest that semaglutide modestly impairs bone health. PYY3-36 treatment led to deteriorated bone markers and increased resorption, potentially limiting its clinical application. Semaglutide and PYY3-36 in combination further aggravate bone loss in MetOP. These findings highlight the need to evaluate gut hormone-based weight loss strategies for long-term skeletal safety, especially in the vulnerable setting of pre-existing osteoporosis.
Behavioral Processes Underlying Oxytocin-Induced Group Cohesion in Free-Ranging Horses.
This study found by contrast, we found no consistent evidence that the effects of oxytocin depended on individuals' centrality or dominance. Examined the effects of intranasal oxytocin administration on social interactions in a feeding context (i.e.
Kobayashi C, Palacino-González G, Brooks J, Yamamoto S
Oxytocin, a neuropeptide hormone, has been suggested to contribute to group cohesion. However, previous studies have primarily focused on interactions at the individual or dyadic level, leaving limited direct evidence regarding how oxytocin influences behavior within established social groups. In this study, we examined the effects of intranasal oxytocin administration on social interactions in a feeding context (i.e. affiliative co-feeding or competition over spatially distributed food patches) in semi-free-ranging captive horse groups. Specifically, we asked two questions: first, which types of social interactions are altered by oxytocin; and second, whether these effects depend on individuals' social positions within the group, namely centrality and dominance. We used drone recording and machine-learning-based tracking to detect co-feeding in the same food patch and approaches toward occupied patches, while aggression was recorded through direct behavioral observation. The results showed that oxytocin affected the tolerance of approaches according to pre-existing affiliative relationships but did not consistently affect active approaches or aggression. Specifically, oxytocin redistributed social tolerance from strongly affiliated partners toward more weakly affiliated partners. By contrast, we found no consistent evidence that the effects of oxytocin depended on individuals' centrality or dominance. This study emphasizes the importance of examining oxytocin effects on social interactions in established groups, in addition to traditional dyadic paradigms. The combination of drone-based observation and machine-learning-based tracking provides a high-resolution framework for quantitative comparative analyses, which should advance our understanding of the behavioral processes through which oxytocin shapes social organization.
Serum vitamin D, innate immunity markers, and biofilm presence as determinants of therapeutic strategies in diabetic foot infections: A comparative cross-sectional study.
In a clinical study, among the 182 biofilm-forming bacterial isolates, 87.4% were isolated from patients undergoing SM and 12.6% from those receiving MM.SummaryLower serum vitamin D, VDR, and LL-37 levels, together with a higher prevalence of biofilm-forming bacteria, were associated with greater DFI severity and an increased likelihood of SM.
Benson R, Jacob Kurian S, Seetharam Shiva P, Banerjee B, Sudha Gururaj VK, Kunhikatta V, Velladath SU, Rodrigues GS, Hariharapura RC, Rao M, Munisamy M, Vishwanath S, Mukhopadhyay C, Miraj SS
BackgroundSevere diabetic foot infections (DFIs) often require surgical management (SM), whereas less severe infections may be managed medically (MM). Vitamin D, its receptor (VDR), and LL-37 play key roles in innate immunity, wound healing, and antimicrobial defense.AimTo determine the association between serum vitamin D, VDR, and LL-37 levels and the prevalence of biofilm-forming bacteria in SM and MM in patients with DFIs.Methods207 patients with DFIs were recruited from the Department of General Surgery, Kasturba Hospital, Manipal, India, between September 2022 and September 2025. Treatment allocation (SM or MM) was determined by the attending surgeons based on DFI severity. At 24 h after treatment initiation, blood samples were collected for vitamin D assessment (electrochemiluminescence immunoassay) and VDR and LL-37 quantification using enzyme-linked immunosorbent assay. Biofilm formation was analyzed using the tissue culture plate method.ResultsOf the 207 participants, 169 (81.64%) required SM and 38 (18.36%) received MM. Patients with SM had significantly lower median levels of vitamin D (12.6 vs. 24.3 ng/mL), VDR (0.69 vs. 1.34 ng/mL), and LL-37 (1.28 vs. 2.46 ng/mL) compared to those with MM (all p < 0.001). SM was significantly associated with DFI severity (p = 0.004) and CRP levels (p = 0.034) after adjusting confounders. Among the 182 biofilm-forming bacterial isolates, 87.4% were isolated from patients undergoing SM and 12.6% from those receiving MM (p < 0.001).SummaryLower serum vitamin D, VDR, and LL-37 levels, together with a higher prevalence of biofilm-forming bacteria, were associated with greater DFI severity and an increased likelihood of SM.
Lysosome-Targeted Iridium(III)-BODIPY Conjugates with GSH-Activatable Reactive Oxygen Species Generation for Enhanced Photodynamic Immunotherapy of Melanoma.
In lab experiments, both in lab cells and in living animals studies demonstrated their excellent biocompatibility, strong photodynamic anticancer efficiency, and significant tumor growth inhibition, highlighting their potential as promising candidates for melanoma treatment.
Zhang J, Jin L, Yang J, Chen S, Yu X, Zheng F, Yuan F, Kou J, Zhu Y, Ren W
Melanoma represents a major clinical challenge due to its aggressive nature, high metastatic potential, and resistance to conventional therapies. Herein, we developed two near-infrared iridium(III)-BODIPY conjugates (BODIPY-1-Ir and BODIPY-2-Ir) for glutathione (GSH)-activated photodynamic immunotherapy. These conjugates function as lysosome-targeting photosensitizers that deplete intracellular GSH to disrupt redox balance and enhance reactive oxygen species generation with light irradiation. The phototoxicity further induces cascading dendritic cell maturation and tumor-associated macrophage reprogramming, promoting immunogenic cell death. Both in vitro and in vivo studies demonstrated their excellent biocompatibility, strong photodynamic anticancer efficiency, and significant tumor growth inhibition, highlighting their potential as promising candidates for melanoma treatment.
GLP-1 dose escalation and disputed ignition interlock alcohol results: Case report.
In a case report, this mechanism should be considered when evaluating disputed ignition interlock violations in individuals using GLP-1 receptor agonists.
Olson A
Ignition interlock breath alcohol devices use electrochemical fuel-cell technology to detect alcohol in breath. Although these devices are intended to detect ethanol, fuel-cell sensors also detect other alcohols, including isopropanol. Prior reports have described false-positive breath alcohol results in individuals with increased ketone body production, including a case involving a very-low-calorie ketogenic diet and another involving diabetic ketoacidosis. This report involves a 45-year-old woman prescribed Wegovy, a GLP-1 receptor agonist, who had two positive ignition interlock results within days of a dose increase from 1.0 mg to 1.7 mg. The individual denied alcohol consumption, testified regarding several years of sobriety, and otherwise maintained employment and compliance with ignition interlock requirements. One plausible explanation for the positive results is that reduced caloric intake following the GLP-1 dose escalation increased reliance on fat metabolism. This may have triggered an increased endogenous acetone production and subsequent reduction of acetone to isopropanol. Isopropanol undergoes electrochemical oxidation on fuel-cell-based breath alcohol sensors and can produce an apparent alcohol-positive result despite not drinking alcohol. This mechanism should be considered when evaluating disputed ignition interlock violations in individuals using GLP-1 receptor agonists.
Real-world effectiveness of tirzepatide in individuals with obesity: weight response, treatment-related factors and diabetes status.
This study found residual differences at longer follow-up may reflect additional unmeasured clinical, metabolic, and treatment-related factors. Aimed to compare anthropometric and metabolic outcomes in these populations, as well as treatment persistence, discontinuation, and the influence of prior GLP-1 receptor agonist (GLP-1 RA) exposure.
Parrotta ME, Milani I, Chinucci M, Occhipinti F, Gintoli E, Franco F, Sanci G, Sbraccia P, Capoccia D, Guglielmi V
Tirzepatide reduces body weight and improves glycemic control, but real-world comparisons between individuals with obesity with and without type 2 diabetes (T2D) remain limited, as well as the potential influence on weight-loss response of baseline characteristics (especially sex and previous treatment exposure). We aimed to compare anthropometric and metabolic outcomes in these populations, as well as treatment persistence, discontinuation, and the influence of prior GLP-1 receptor agonist (GLP-1 RA) exposure. This retrospective multicenter study included adults with overweight/obesity without T2D (Ob) or with T2D (ObT2D) treated with tirzepatide. Data were collected at baseline and after 2-4 (T1), 5-8 (T2), and 9-15 (T3) months. Longitudinal changes were assessed using linear mixed-effects models, and multivariable analyses identified predictors of weight loss. Ob participants (n=210, 74.8% female) were younger, had higher BMI, better glycemic control, and less previous GLP-1RA exposure than ObT2D participants (n=378, 49.7% female) (45.7% vs 79.3%; p<0.001). Weight loss was greater in Ob than ObT2D at all follow-ups (-5.0% vs -2.8%, -10.1% vs -3.3%, and -14.2% vs -4.7%; all p≤0.011), with mixed-effects models confirming different trajectories. This difference was attenuated and no longer statistically significant when analyses were restricted to treatment-naïve participants. Prior GLP-1RA exposure was independently associated with lower weight loss, while an interaction between prior GLP-1RA exposure and T2D status emerged at longer follow-up. No effect modification by sex or age was clearly detectable in this cohort. Discontinuation was more frequent in Ob, with adverse events, and financial barriers among the main reported reasons. Adverse events occurred in 16.9%, were mainly mild, transient gastrointestinal events, more frequent in Ob than ObT2D (26.9% vs 11.1%; p<0.001). Tirzepatide was effective and well tolerated in routine practice. Greater weight loss occurred in obesity without T2D, while prior GLP-1RA exposure was independently associated with a reduced weight response. Previous GLP1-RA exposure may partly account for the different weight-loss trajectories observed between obesity with and without T2D. Residual differences at longer follow-up may reflect additional unmeasured clinical, metabolic, and treatment-related factors.
The Skin-Mood Axis in Midlife: Neuro-Immuno-Endocrine Cross-Talk in Perimenopausal and Menopausal Aesthetic Dermatology.
In a research review, recognizing the skin-mood axis may help aesthetic dermatologists individualize consultation, sequence treatments around tissue quality and recovery capacity, and align procedural choices with patient motivation and realistic patient-centered outcomes.
Shaker G, Humphrey S, Aguilera SB, Fabi SG
Perimenopause and menopause may alter skin quality, repair capacity, sleep, mood, self-perception, and aesthetic motivation, yet midlife aesthetic aging is often framed primarily around estrogen and collagen loss. To propose a midlife skin-mood axis that integrates cutaneous biology, neuroendocrine signaling, immune activity, and psychosocial experience in perimenopausal and menopausal aesthetic dermatology. This narrative review synthesizes evidence regarding menopausal hormonal change, barrier and extracellular matrix remodeling, stress and sleep physiology, oxytocin-related signaling, body image, observer perception, and aesthetic motivation. Midlife skin concerns may reflect interactions among reduced barrier resilience, altered repair capacity, neuroendocrine stress pathways, and changes in self-perception rather than isolated tissue aging. These relationships may influence tissue readiness, consultation goals, recovery counseling, patient-reported outcomes, and treatment satisfaction. Recognizing the skin-mood axis may help aesthetic dermatologists individualize consultation, sequence treatments around tissue quality and recovery capacity, and align procedural choices with patient motivation and realistic patient-centered outcomes.
GLP-1-based Therapies in MASH: From Metabolic Benefits to an Improvement in Liver Fibrosis.
In a research review, this review summarizes the evidence, mechanisms, patient selection, safety, monitoring, and challenges.
Takami T
The fibrosis stage is the strongest predictor of liver-related outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD), supporting pharmacotherapy for metabolic dysfunction-associated steatohepatitis (MASH) with F2-F3 fibrosis. Glucagon-like peptide-1 (GLP-1) receptor agonists improve MASLD through weight loss and favorable metabolic and anti-inflammatory effects; preclinical studies suggest weight loss-independent signaling mediated by liver sinusoidal endothelial cells. Early trials showed steatohepatitis resolution, but an inconsistent fibrosis improvement. In phase III ESSENCE, weekly semaglutide 2.4 mg significantly increased the proportions of patients achieving "resolution of steatohepatitis with no worsening of liver fibrosis" and a "reduction in liver fibrosis with no worsening of steatohepatitis" at week 72, leading to accelerated approval in the United States and approval in Japan for noncirrhotic MASH with moderate or advanced fibrosis. Non-invasive assessment may support patient selection and monitoring when a biopsy is inappropriate, although response thresholds require validation. This review summarizes the evidence, mechanisms, patient selection, safety, monitoring, and challenges.